UNSPSC 51392402: Dobutamine

This classification denotes an adrenergic agent with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3S12J47372, chemically known as 1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (+-)- but generally known as dobutamine, which bears US NIH Compound Identifier 36811. European Medicines Agency schedules Dobutamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06343MIG.

UNSPSC 51392402 Dobutamine is a Commodity code for a specific pharmaceutical product—a sympathomimetic agent used in acute care settings—but the recent state and local opportunities tagged under this code show little alignment with dobutamine procurement itself. Instead, the posted solicitations address broader pharmacy and pharmaceutical-access initiatives: Seminole County, Florida is sourcing naloxone and drug deactivation systems through competitive bidding, and the Texas Health and Human Services Commission has issued a Request for Information on direct-to-manufacturer prescription programs. These mismatches suggest that state and local procurement systems are tagging opportunities with pharmaceutical-category codes that do not precisely match the goods and services being solicited, or that the code bucket captures a wider range of pharmaceutical-related activity than its narrow product name implies.

The issuing bodies include county health departments (Seminole County) and state health and human services agencies (Texas HHS Commission), indicating that pharmaceutical procurement under this code spans community health operations and state-level pharmacy benefit administration. Geographically, recent activity appears in Florida and Texas. The Seminole County IFB (IFB60459723LAS) sought 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the Texas HHS RFI (HHS0017013) posted April 3, 2026, explored vendor capabilities for direct manufacturer-to-payer prescription programs without formal competitive parameters. Neither solicitation directly targets dobutamine supply or procurement.